Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 28OTHER 14NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Mesothelioma 1Breast Neoplasms 1

Interventions

Specimen Handling 40Biopsy 39Magnetic Resonance Spectroscopy 31Cyclophosphamide 21aldesleukin 20fludarabine 16fludarabine phosphate 13Leucovorin 12Fluorouracil 12Interleukin-2 11Paclitaxel 9Melphalan 9Oxaliplatin 8trastuzumab deruxtecan 7Irinotecan 7X-Rays 6Taxes 6Nivolumab 6olaparib 5Ipilimumab 5CTLA-4 Antigen 5trametinib 4Neoadjuvant Therapy 4Floxuridine 4Doxorubicin 4Chemotherapy, Adjuvant 4Carboplatin 4veliparib 3talazoparib 3pembrolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm Metastasis × 130-nm albumin-bound paclitaxel × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡